Tanya Siddiqi, MD, discusses how she sees acalabrutinib fitting into the treatment landscape for patients with chronic lymphocytic leukemia following the results from the phase III ASCEND trial.
Tanya Siddiqi, MD
Articles by Tanya Siddiqi, MD
Latest Updated Articles
Acalabrutinib Appears Promising as Monotherapy in CLLPublished: September 16th 2019 | Updated: